Clinical Trial Update: Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for COVID-19 pneumonia using cryopreserved allogeneic P_MMSCs and UC-MMSCs across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• P_MMSCs
• UC-MMSCs

Snippet

Sponsor: Institute of Cell Therapy | Conditions: COVID-19 Pneumonia | Phase 1, Phase 2 | Status: UNKNOWN